Inova Labs (Austin, TX) a medical device company focused on the development, manufacturing, and worldwide distribution of medical devices used to treat Chronic Obstructive Pulmonary Disease, closed a $17.5 million in Series B financing. Participants include Latterell Venture Partners, Gilde Healthcare Partners and Three Arch Partners.

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

PathoGenetix (Woburn, MA) a development-stage sequencing company focused on simultaneous identification and characterization of bacterial strains in a single test, closed a $7.5M Series B financing, bringing the total round to $11.5M. Participants include Ascension Health Ventures, Excel Venture Management, CB Health Ventures and HealthCare Ventures.

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital
Thanx for your patience as we catch-up.

Breathe America (Nashville, TN) a commercial-stage clinical company focused on the treatment of chronic airway diseases, allergy, sinus and asthma, closed a $22M Series B financing. Participants include Essex Woodlands.
Thanx for your patience as we catch-up.

SeeChange Health (San Francisco, CA) a commercial-stage health management company focused on data analytics and interactive personal health records, closed a $20M Series B financing. Participants include Maverick Capital and Psilos Group.
Thanx for your patience as we catch-up.

Circle Cardiovascular Imaging (Canada) a commercial-stage analytical software company focused on cardiac imaging, closed a $3.9M Series B financing. Participants include Business Development Bank of Canada, Foundation Equity and First Yellowhead Equities.
Thanx for your patience as we catch-up.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.
Thanx for your patience as we catch-up.

Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.
Thanx for your patience as we catch-up.

nanoMR (Albuquerque, NM) a development stage medical device focused on a immunomagnetic capture system for the blood culture market, closed a $13M Series B financing. Participants include Excel Venture Management, Healthcare Ventures, vSpring Capital, Dow Chemical Company and Sun Mountain Capital.
Thanx for your patience as we catch-up.